Pharmaceutical company Abbvie had its shares drop about 3% last week after California’s insurance commissioner Dave Jones sued the company, alleging Abbvie has been providing kickbacks in the form of nursing support and insurance assistance to prompt doctors to write prescriptions for its arthritis drug Humira.
Mr. Jones, who filed a complaint in Alameda County Superior Court, alleges the company’s “Ambassador” program was intended to “keep patients on a dangerous drug at any cost.”
AbbVie claimed in a statement that it “operates in compliance with the many state and federal laws that govern interactions with healthcare providers and patients.”
Credit Suisse analysts said that the lawsuit could have extensive repercussions in the drug industry since the kickback practices “are similar to what other biopharma companies have also used to help patients start and stay on medications that their doctor prescribes.”
Full Content: Bloomberg & The Wall Street Journal
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI